Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Chester County-based Annovis Bio, Inc. (NYSE: ANVS) is set to make a significant impact at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) in Lisbon, …
Annovis Bio to Shed Light on Neurodegenerative Diseases at International Conference Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a Pennsylvania-based clinical-stage drug platform company, has announced the completion of the last patient visit in the phase II/III study of its …
Annovis Bio Wraps Up Phase II/III Trial for Alzheimer’s Drug Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a leading biopharmaceutical company, announced this week the filing of a patent application that covers the use of buntanetap and its analogues …
Annovis Bio Files Patent for Novel Mental Illness Treatment Using Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS this week announced a delay in the release of Phase III study data for its promising Parkinson’s Disease drug, buntanetap. The postponement …
Annovis Bio Postpones Release of Phase III Data for Parkinson’s Disease Drug, Buntanetap Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …
Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More BERWYN, PA — In a recent announcement, Berwyn, Pennsylvania-based clinical-stage drug platform company Annovis Bio, Inc. (NYSE: ANVS) has appointed Andrew Walsh as its new Vice President of Finance. This …
Andrew Walsh Joins Annovis Bio as VP of Finance Amid Pivotal Clinical Trials Read More BERWYN, PA — Chester County-based biopharmaceutical company Annovis Bio, Inc. (NYSE: ANVS) announced this week that its phase II/III study of buntanetap, a potential treatment for Alzheimer’s Disease (AD), has …
Annovis Bio’s Phase II/III Study of Buntanetap Exceeds Full Enrollment Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments.
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update Read More BERWYN, PA — In a recent breakthrough, Annovis Bio (NYSE: ANVS), a biopharmaceutical company, has successfully performed measurements of critical biomarkers in the plasma of Parkinson’s disease patients. Utilizing buntanetap, …
Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases, recently announced a significant milestone in its clinical trial journey. The …
Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward Read More